According to calculations by Morrison & Foerster LLP's Biometer, the average up-front payment for biotech deals in the third quarter came in at $43.7 million, up from $30.4 million in the year-ago quarter. Read More
With investors focused on the performance of large cap biotech companies and their third quarter earnings the early returns have, by and large, been positive. As a result, as we close the curtain on what has been an extremely turbulent capital market environment in October, biotech has emerged relatively unscathed and is poised to finish the year in good shape. Read More
